Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Q4, Full-Year Preliminary Revenues Beat Analysts' Estimate

NEW YORK (GenomeWeb) – Exact Sciences reported on Sunday that it expects fourth quarter revenues of $34.9 million to $35.4 million, and FY 2016 revenues of $99.0 million to $99.5 million.

The firm's preliminary revenues soundly beat the average Wall Street estimate of $30.2 million for Q4 and $94.2 million for 2016.

Exact also reported that it completed approximately 82,000 Cologuard colon cancer tests during the fourth quarter, a 114 percent jump from the same period of 2015. In 2016, the company completed 244,000 tests Cologuard, a 134 percent increase from 2015.

Further, more than 9,500 health care providers ordered Cologuard for the first time during Q4, and the number of providers who have ordered Cologuard since it was launched increased to nearly 60,000 during 2016, an increase of 122 percent from the prior year.

"Cologuard is becoming a standard of care for 80 million Americans who should be screened for colon cancer," said Exact Chairman and CEO Kevin Conroy in a statement. "Strong demand for Cologuard from both patients and healthcare providers reflects the great need for this innovative, easy-to-use colon cancer screening test."

Exact's shares rose more than 14 percent to $17.28 in morning trading on the Nasdaq.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.